Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Braeburn Pharmaceuticals has expanded its current therapeutic pipeline with the acquisition of an implantable, six-month formulation of the second-generation antipsychotic, risperidone, to treat schizophrenia from Endo Pharmaceuticals.
Subscribe to our email newsletter
The acquisition of this product will help the company focus beyond addiction and pain to include schizophrenia and other serious psychiatric disorders.
With the acquisition of risperidone, Braeburn acquires global rights to other potential applications of the implant platform technology known as the MedLaunch Implant Program.
Additionally, Braeburn has also licensed development and commercialization rights from Oncothyreon to ATI-9242, a new, atypical antipsychotic compound designed to treat schizophrenia.
ATI-9242 is a new, antipsychotic with broad effect but minimal side effects with potential to fill continued unmet need in treatment of schizophrenia and other serious psychiatric disorders.
Aryx Therapeutics has designed ATI-9242 to have many of the benefits of clozapine but without the well-documented adverse effects of clozapine.
Currently, Risperidone is the leading agent used to treat schizophrenia and has a well-established record of safety and effectiveness.
Braeburn Pharmaceuticals president and CEO Behshad Sheldon said: "The risperidone six-month implant and ATI-9242 provide two distinct opportunities to help patients manage schizophrenia.
"With these new promising assets, Braeburn continues its commitment to developing long-acting implantable and injectable treatments where additional options are acutely needed."
According to the company, daily dosing of risperidone is particularly challenging for patients with schizophrenia where improvement in symptoms often leads to discontinuation of medication.
Apart from developing new formulations to improve existing therapies, Braeburn also develops next generation of therapies by exploring promising new molecules.